0013656 2025 RIV GB eng J
Čuřík, Nikola - Láznička, Adam - Polívková, Václava - Křížková, Jitka - Pokorná, E. - Semerák, Pavel - Suchánková, Pavla - Burda, Pavel - Hochhaus, A. - Machová Poláková, Kateřina^G
Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations.
Leukemia. Vol. 38, no. 6 (2024), s. 1415-1418. ISSN 0887-6924
Grant: Ministerstvo zdravotnictví NU21-07-00225
Institucionální podpora: RVO:00023736
Klíčová slova: ponatinib * asciminib * chronic myeloid leukemia
Cite Score: 18.500, rok: 2024; SJR: 3.458, rok: 2024; IF: 13.4, rok: 2024
DOI: 10.1038/s41375-024-02248-0

Anotace: Despite significant progress in chronic myeloid leukemia (CML) therapy over recent decades, the blast crisis (BC) remains a therapeutic challenge. This advanced disease stage exhibits clonal, genomic, and molecular heterogeneity, often featuring additional chromosomal aberrations and mutations in the BCR::ABL1 kinase domain and/or other leukemia-related genes. n this study, a murine model of polyclonal aggressive myeloid CML-BC was established using imatinib/ponatinib cross-resistant (IMP-R) clones to evaluate the efficacy of ponatinib, asciminib, venetoclax, and their combinations in vivo within a CDX (cell line-derived xenograft) context.